Janus Henderson Group’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.12M | Hold |
68,191
| – | – | ﹤0.01% | 949 |
|
|
2025
Q4 | $5.4M | Buy |
68,191
+4,314
| +7% | +$325K | ﹤0.01% | 911 |
|
|
2025
Q3 | $4.18M | Hold |
63,877
| – | – | ﹤0.01% | 980 |
|
|
2025
Q2 | $2.52M | Hold |
63,877
| – | – | ﹤0.01% | 1180 |
|
|
2025
Q1 | $1.99M | Hold |
63,877
| – | – | ﹤0.01% | 1279 |
|
|
2024
Q4 | $2.23M | Buy |
63,877
+4,900
| +8% | +$183K | ﹤0.01% | 1254 |
|
|
2024
Q3 | $2.36M | Hold |
58,977
| – | – | ﹤0.01% | 1228 |
|
|
2024
Q2 | $2.81M | Sell |
58,977
-740
| -1% | -$30.4K | ﹤0.01% | 1096 |
|
|
2024
Q1 | $2.59M | Buy |
59,717
+14
| +0% | +$667 | ﹤0.01% | 1168 |
|
|
2023
Q4 | $3.02M | Sell |
59,703
-103
| -0.2% | -$4.93K | ﹤0.01% | 1041 |
|
|
2023
Q3 | $2.71M | Buy |
59,806
+4
| +0% | +$165 | ﹤0.01% | 1029 |
|
|
2023
Q2 | $2.45M | Sell |
59,802
-57
| -0.1% | -$2.19K | ﹤0.01% | 1140 |
|
|
2023
Q1 | $2.14M | Buy |
59,859
+6,137
| +11% | +$230K | ﹤0.01% | 1216 |
|
|
2022
Q4 | $2.03M | Buy |
53,722
+7,442
| +16% | +$313K | ﹤0.01% | 1092 |
|
|
2022
Q3 | $2.05M | Buy |
46,280
+23,073
| +99% | +$972K | ﹤0.01% | 1278 |
|
|
2022
Q2 | $858K | Sell |
23,207
-2,516
| -10% | -$94.9K | ﹤0.01% | 1424 |
|
|
2022
Q1 | $953K | Buy |
25,723
+7
| +0% | +$229 | ﹤0.01% | 1546 |
|
|
2021
Q4 | $783K | Buy |
25,716
+11,968
| +87% | +$377K | ﹤0.01% | 1619 |
|
|
2021
Q3 | $461K | Buy |
+13,748
| New | +$518K | ﹤0.01% | 1656 |
|
|
2021
Q2 | – | Sell |
-76,644
| Closed | -$3.45M | – | 1637 |
|
|
2021
Q1 | $3.45M | Buy |
76,644
+26,018
| +51% | +$1.45M | ﹤0.01% | 1086 |
|
|
2020
Q4 | $2.86M | Sell |
50,626
-10,053
| -17% | -$501K | ﹤0.01% | 1070 |
|
|
2020
Q3 | $2.88M | Sell |
60,679
-8,848
| -13% | -$491K | ﹤0.01% | 995 |
|
|
2020
Q2 | $4.1M | Buy |
69,527
+22,253
| +47% | +$1.24M | ﹤0.01% | 944 |
|
|
2020
Q1 | $2.24M | Sell |
47,274
-154,438
| -77% | -$8.61M | ﹤0.01% | 990 |
|
|
2019
Q4 | $12.2M | Sell |
201,712
-380,819
| -65% | -$22.7M | 0.01% | 929 |
|
|
2019
Q3 | $34.9M | Buy |
582,531
+274,852
| +89% | +$17.9M | 0.02% | 689 |
|
|
2019
Q2 | $19.8M | Buy |
307,679
+211,161
| +219% | +$14.9M | 0.01% | 796 |
|
|
2019
Q1 | $7.83M | Buy |
96,518
+84,587
| +709% | +$5.46M | ﹤0.01% | 939 |
|
|
2018
Q4 | $645K | Buy |
+11,931
| New | +$609K | ﹤0.01% | 1206 |
|
|
2018
Q2 | – | Sell |
-14,300
| Closed | -$630K | – | 1412 |
|
|
2018
Q1 | $630K | Buy |
+14,300
| New | +$726K | ﹤0.01% | 1266 |
|
|
2016
Q3 | – | Sell |
-12,763
| Closed | -$297K | – | 831 |
|
|
2016
Q2 | $297K | Hold |
12,763
| – | – | ﹤0.01% | 797 |
|
|
2016
Q1 | $517K | Hold |
12,763
| – | – | ﹤0.01% | 755 |
|
|
2015
Q4 | $791K | Hold |
12,763
| – | – | 0.01% | 682 |
|
|
2015
Q3 | $516K | Hold |
12,763
| – | – | ﹤0.01% | 737 |
|
|
2015
Q2 | $734K | Hold |
12,763
| – | – | 0.01% | 734 |
|
|
2015
Q1 | $812K | Buy |
+12,763
| New | +$866K | 0.01% | 727 |
|
Other funds holding IONS
VPM
VCM
Janus Henderson Group's IONS Position: Q1 2026 in Review
Janus Henderson Group held its Ionis Pharmaceuticals (IONS) position steady in Q1 2026 at 68,191 shares worth $5.12M. The position accounts for ﹤0.01% of the portfolio, ranked #949.
Janus Henderson Group first reported a position in IONS in Q1 2015 and has held it in 36 quarters since. The position peaked at $34.9M in Q3 2019. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Janus Henderson Group held 68,191 shares of Ionis Pharmaceuticals worth $5.12M as of Q1 2026.
- Janus Henderson Group left its Ionis Pharmaceuticals share count unchanged in Q1 2026.
- Ionis Pharmaceuticals made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #949 holding.
- Janus Henderson Group first reported a position in Ionis Pharmaceuticals in Q1 2015 and has held it in 36 quarters since.
- Janus Henderson Group's Ionis Pharmaceuticals position peaked at $34.9M in Q3 2019.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.